Saudi Arabia is no longer only talking about becoming a biotechnology leader — it is building the ecosystem to become one. Under Vision 2030 and the National Biotechnology Strategy, the Kingdom is assembling the research, clinical, manufacturing, regulatory and investment capabilities that define a mature advanced-therapies market.
Advanced Therapies World brings that story into focus. Ahead of the event, here are seven forces shaping Saudi Arabia’s advanced-therapies future — and the questions the global community will gather in Riyadh to answer.
1. What Will Turn National Ambition into Delivery? Building the Ecosystem for Scale
Saudi Arabia is moving beyond strategy into delivery. The National Biotechnology Strategy sets a clear destination — regional leadership across MENA by 2030 and a global position by 2040 — backed by targets of 11,000 high-quality biotech jobs by 2030, rising to 55,000 by 2040, and a contribution of more than USD 34.6 billion to non-oil GDP by 2040. Coordinated national effort now spans research, clinical development, manufacturing and regulation. The question is no longer whether the vision is bold enough, but how quickly it translates into infrastructure, capability and measurable progress on the ground.
2. How Can Localization Scale? Building Manufacturing Capacity and Health Security
Biotech in Saudi Arabia is being built as critical national infrastructure. From GMP facilities and bioprocessing centres to CDMO partnerships, localization sits at the centre of the strategy — improving access, reducing import dependency and strengthening long-term health security. The clearest proof point is already clinical: specialist institutions such as King Faisal Specialist Hospital & Research Centre are manufacturing CAR-T locally and treating patients with it. Riyadh will examine how that domestic capability is being prioritized, funded and scaled from single sites into a national system.
3. What Should Biotech Investment Deliver? Moving from Data to National Impact
In Saudi Arabia, biotech investment is shaped less by hype cycles than by national priorities. Sovereign and strategic capital — from the Public Investment Fund and Sanabil to dedicated new biotech funds — is being deployed with an eye on patient outcomes, workforce development and ecosystem growth, not only on a promising data readout. For founders and investors alike, this reframes what value creation means in a market defined by long-term impact, and it changes the questions asked in the room.
4. Who Will Run the System? Building the Workforce for Scale
A cleanroom is a powerful signal of intent, but it does not release a batch, resolve a deviation or monitor a patient — experienced people do. With a young population and a deliberate push through national training centres, academic programmes and international partnerships, Saudi Arabia has a rare opportunity to build a world-class biotech workforce. The harder task is turning 11,000 jobs by 2030 into genuine capability: people who can translate a research method into a controlled process, challenge a batch record, and hold the authority to stop production when needed. The workforce question is really an operating-system question — and it may be the single force that decides how fast the rest can move.
5. Can Saudi Arabia Become a Global Clinical Trials Hub? Unlocking Population, Data and Trial Potential
Saudi Arabia offers a differentiated clinical landscape: distinctive patient populations, a high prevalence of genetic disease and increasingly integrated health-data systems. That combination is already producing results — KFSHRC reports more than 200 patients treated with CAR-T since 2020, and the SFDA has approved the first advanced-therapy study developed inside the Kingdom. Together these position Saudi Arabia as an emerging hub for clinical trials and translational research with genuine global relevance, not simply a site that hosts studies designed elsewhere.
6. What Makes a Global Partnership Work? Turning International Expertise into Local Capability
International collaboration is critical to accelerating progress, and Saudi Arabia is actively partnering with global biotech, pharma and technology companies to bring in expertise, investment and innovation. The most interesting question is how those partnerships are structured. A transactional deal can deliver a product; a capability-building partnership leaves behind trained people, validated methods and local decision rights. The technology partnerships already anchoring local CAR-T manufacturing hint at what the more durable model looks like — one measured by what stays behind, not only by what arrives.
7. Can Regulation Become a Competitive Advantage? Designing a New Model for Advanced Therapies
Rather than adapting legacy systems, Saudi Arabia has the opportunity to design a modern, agile framework for advanced therapies from first principles. The SFDA is building a more explicit regulatory pathway for cell and gene therapies and clinical research, and national data platforms and integrated healthcare delivery are being developed alongside it. Done well, the Kingdom could stand up a system that serves as a model for other emerging markets navigating the same transition — turning regulatory design itself into a competitive advantage.
Be Part of What Comes Next in Riyadh
If you’re inspired by the momentum building across Saudi Arabia’s advanced therapies landscape, there’s no better place to experience it firsthand.
Join global leaders, innovators, and investors at Advanced Therapies World in Riyadh, taking place at the Teatro Venue, Riyadh, on 5–6 December, organized by Phacilitate.
This is a unique opportunity to:
Secure your place and be part of the future of advanced therapies in Saudi Arabia
)